Clinical Trials Browser

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT07081646 2026-03-24

ALACRITY

Phase 1/2 Recruiting

91 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07250269 2026-03-24

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Phase 1 Recruiting

9 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

125 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT07224672 2026-03-17

ALANIS

Phase 2 Not yet recruiting

60 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Phase NA Recruiting

41 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01758042 2026-03-06

BMT

Phase NA Completed

10 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Anemia, Aplastic, Anemia, Sickle Cell, Autoimmune Diseases, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Thalassemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Anemia, Diamond-Blackfan, Renal Insufficiency, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT06569147 2026-03-06

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

49 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Phase 1 Active not recruiting

21 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

15 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT06963216 2026-02-27

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Phase 3 Recruiting

15 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Phase 1 Active not recruiting

11 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05145816 2026-02-17

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

37 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Clinical Trials

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

ETCABIO

ALACRITY

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

ALANIS

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

BMT

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis